Rein Therapeutics, Inc. (RNTX)
0.791
-0.01
(-1.12%)
USD |
NASDAQ |
Sep 21, 16:00
0.791
0.00 (0.00%)
After-Hours: 20:00
Rein Therapeutics EPS Diluted (Quarterly) : -0.095 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.095 |
| March 31, 2026 | -0.1923 |
| December 31, 2025 | -1.219 |
| September 30, 2025 | -0.2117 |
| June 30, 2025 | -0.2821 |
| March 31, 2025 | -0.251 |
| December 31, 2024 | -1.892 |
| September 30, 2024 | -0.2699 |
| June 30, 2024 | -0.4491 |
| March 31, 2024 | -0.8568 |
| December 31, 2023 | -1.539 |
| September 30, 2023 | -0.4023 |
| June 30, 2023 | -0.3935 |
| March 31, 2023 | -1.052 |
| December 31, 2022 | -1.001 |
| September 30, 2022 | -1.402 |
| June 30, 2022 | -1.760 |
| March 31, 2022 | -1.858 |
| December 31, 2021 | -1.501 |
| September 30, 2021 | -1.481 |
| June 30, 2021 | -1.257 |
| March 31, 2021 | -1.673 |
| December 31, 2020 | -2.405 |
| Date | Value |
|---|---|
| September 30, 2020 | -2.555 |
| June 30, 2020 | -2.812 |
| March 31, 2020 | -4.853 |
| December 31, 2019 | -5.204 |
| September 30, 2019 | -5.573 |
| June 30, 2019 | -5.422 |
| March 31, 2019 | -9.737 |
| December 31, 2018 | -9.540 |
| September 30, 2018 | -10.09 |
| June 30, 2018 | -12.80 |
| March 31, 2018 | -10.40 |
| December 31, 2017 | -9.40 |
| September 30, 2017 | -9.00 |
| June 30, 2017 | -6.722 |
| March 31, 2017 | -6.223 |
| December 31, 2015 | -4.521 |
| September 30, 2015 | -4.377 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -4.594 |
| September 30, 2014 | -4.559 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.375M |
| Total Expenses (Quarterly) | 6.375M |
| Enterprise Value | 72.97M |
| Earnings Yield | -217.2% |
| Normalized Earnings Yield | -120.37 |